|
| Dinamica numărului de publicaţii pe ani |  |  |
| Dinamica articolelor pe ani |  |
| Distribuirea numărului de pagini publicate pe categorii de reviste și ani | |
| Distribuirea articolelor pe domenii şi ani | |  | |
| Colaborarea autorului |  |  |
| Dinamica descărcărilor pe ani | |
| Proiecte | (1) |
Google Scholar IDORCiDScopus Author IDArticole în reviste din RM - 16. Publicaţii peste hotare - 9.Publicații indexate în SCOPUS -
8.
- 3. Articole în reviste din RM
- 3.1. Articole în reviste științifice din RM (perioada în care au avut categorie de clasificare + 2 numere până la aprobarea statutului de publicație științifică)
- 3.1.3.Articole în reviste de cat. B - 8
- 3.1.4.Articole în reviste de cat. C - 4
- 3.2.Articole în alte reviste din RM - 4
- 4. Articole în reviste de peste hotare
- 4.1.Articole în reviste din WoS - 1
- 4.2.Articole în reviste din Scopus - 8
- 4.3.Articole în alte reviste științifice de peste hotare - 1
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ 2018 - 3
|
A CCR2/5 inhibitor, PF-04634817, is inferior to monthly ranibizumab in the treatment of diabetic macular edema   |
Gale Jeremy D.1 , Berger Brian B.2 , Gilbert Steven3 , Popa Serghei4  , Sultan Marla B.5 , Schachar Ronald A.6 , Girgenti Douglas Q.57 , Perros-Huguet Christelle18 |
1 Pfizer Inc., Inflammation and Immunology Research Unit,
2 Retina Research Center, Austin,
3 Early Clinical Development, Pfizer, Inc, Cambridge, MA,
4 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
5 Global Product Development, Pfizer, Inc, New York, NY,
6 Clinical Affairs, Pfizer Essential Health, Pfizer, Inc, San Diego, CA,
7 Immunology Department, Boehringer Ingelheim, Ridgefield, CT,
8 Research and Development, X-Chem Pharmaceuticals, Waltham, MA |
| Investigative Ophthalmology and Visual Science |
| Nr. 6(59) / 2018 / ISSN 0146-0404 |
| Disponibil online 20 June, 2018. Descarcări-0. Vizualizări-488 |
----------------------------------------------------------------------------------------------------------------------------------- | Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3 |
| Yeh Wendy W.1 , Autor Nou2 , Popa Serghei3 , Ghicavîi Nelea3 , Visan Sorin3 |
1 Merck and Co., Inc., Kenilworth,
2 Necunoscută, SUA,
3 Timofei Moșneaga Republican Clinical Hospital |
| Clinical Therapeutics |
| Nr. 5(40) / 2018 / ISSN 0149-2918 |
| Disponibil online 20 June, 2018. Descarcări-0. Vizualizări-522 |
----------------------------------------------------------------------------------------------------------------------------------- | Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: Evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation |
| Glatt Sophie1 , Baeten Dominique L.P.23 , Baker Terry S.1 , Griffiths Meryn R.1 , Ionescu Lucian2 , Lawson Alastair D.G.1 , Maroof Ash1 , Oliver Ruth1 , Popa Serghei4 , Strimenopoulou Foteini1 , Vajjah Pavan1 , Watling Mark I.L1 , Yeremenko Nataliya G.3 , Miossec Pierre J.5 , Shaw Stevan1 |
1 UCB Pharma, Slough,
2 UCB Pharma, Brussels,
3 University of Amsterdam,
4 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
5 Université Lyon |
| Annals of the Rheumatic Diseases |
| Nr. 4(77) / 2018 / ISSN - / ISSNe 0003-4967 |
| Disponibil online 8 May, 2018. Descarcări-0. Vizualizări-564 |
----------------------------------------------------------------------------------------------------------------------------------- 2017 - 6
|
| A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects |
| Krauwinkel Walter J.J.1 , Noukens Jan2 , Van Dijk Jan1 , Popa Serghei3 , Ouatas Taoufik1 , De Vries Michiel1 , Phung De1 , Gibbons Jacqueline A.4 , Mordenti Joyce J.4 , Mateva Lyudmila5 |
1 Astellas Pharma Europe,
2 Kinesis Pharma BV,
3 Timofei Moșneaga Republican Clinical Hospital,
4 Medivation, Inc,
5 Gastroenterology Clinic, University Hospital St. Ivan Rilski, Medical University Sofia |
| Journal of Clinical Pharmacy and Therapeutics |
| Nr. 3(42) / 2017 / ISSN 0269-4727 |
| Disponibil online 20 February, 2018. Descarcări-0. Vizualizări-595 |
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: A phase II dose-ranging randomised controlled trial |
| Wallace Daniel J.1 , Strand Vibeke2 , Merrill Joan T.3 , Popa Serghei4 , Spindler Alberto J.5 , Eimon Aliciaf6 , Noi Autori |
1 Cedars-Sinai Medical Center, Los Angeles,
2 Stanford University, Palo Alto,
3 Oklahoma Medical Research Foundation, Oklahoma City,
4 Timofei Moșneaga Republican Clinical Hospital,
5 Private Medical Center of Rheumatology, Tucuman,
6 CEMIC, Buenos Aires |
| Annals of the Rheumatic Diseases |
| Nr. 3(76) / 2017 / ISSN - / ISSNe 0003-4967 |
| Disponibil online 10 June, 2022. Descarcări-0. Vizualizări-94 |
----------------------------------------------------------------------------------------------------------------------------------- Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic contrast enhanced assessments with semi-quantitative scoring   |
| Beals Chan R.12 , Baumgartner Richard1 , Peterfy Charles G.3 , Bălănescu Andra Rodica4 , Mirea Gavrila5 , Harabagiu Alexandru6 , Popa Serghei7 , Cheng Amy1 , Feng Dai1 , Ashton Edward A.8 , Di Carlo Julie3 , Vallee Marie Helene1 , Dardzinski Bernard J.19 |
1 Department of Clinical Research, Merck and Co., Inc., Kenilworth,
2 Abide Therapeutics, San Diego,
3 Spire Sciences, Inc., Boca Raton,
4 University of Medicine and Pharmacy “Carol Davilla”, Bucharest,
5 Tractorul County Hospital, Brasov,
6 German Center for Diagnostics,
7 Timofei Moșneaga Republican Clinical Hospital,
8 VirtualScopics, Rochester, NY,
9 Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda |
| PLoS ONE |
| Nr. 12(12) / 2017 / ISSN 1932-6203 |
| Disponibil online 2 February, 2018. Descarcări-0. Vizualizări-599 |
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
